FTC investigates J&J contracts regarding the drugmaker's blockbuster Remicade
In September 2017, Pfizer filed a lawsuit alleging that J&J was colluding with insurers to ensure the company’s blockbuster autoimmune disease drug, Remicade, was given first preference over its cheaper biosimilar. On Monday, J&J disclosed that the US Federal Trade Commission (FTC) was investigating whether the company had violated antitrust laws, in a regulatory filing.
J&J’s Remicade, first approved in 1998, is a biologic used to treat various ailments including rheumatoid arthritis, plaque psoriasis, Crohn’s disease and ulcerative colitis. In the second quarter, the Band-Aid maker generated $1.12 billion in global Remicade sales.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.